Latest news for Mallinckrodt (OTC:MCKPF) Stock

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology, and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which include niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

MALLINCKRODT PB LTD CO by Mallinckrodt plc.

Mallinckrodt PLC

Investors with a lot of money to spend have taken a bullish stance on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with COST, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Costco Wholesale.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 40%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $220,220, and 12 are calls, for a total amount of $739,956.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $600.0 and $1005.0 for Costco Wholesale, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Costco Wholesale options trades today is 334.38 with a total volume of 950.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Costco Wholesale's big money trades within a strike price range of $600.0 to $1005.0 over the last 30 days.
<h3>Costco Wholesale Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721316728_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$8.3</td>
<td>$7.55</td>
<td>$7.93</td>
<td>$880.00</td>
<td>$198.5K</td>
<td style="text-align: right;">960</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$168.5</td>
<td>$164.25</td>
<td>$168.5</td>
<td>$1005.00</td>
<td>$168.5K</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$21.05</td>
<td>$19.05</td>
<td>$21.05</td>
<td>$835.00</td>
<td>$92.6K</td>
<td style="text-align: right;">31</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$252.85</td>
<td>$248.45</td>
<td>$248.45</td>
<td>$600.00</td>
<td>$74.5K</td>
<td style="text-align: right;">19</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$7.9</td>
<td>$7.65</td>
<td>$7.9</td>
<td>$885.00</td>
<td>$72.6K</td>
<td style="text-align: right;">996</td>
<td style="text-align: right;">350</td>
</tr>
</tbody>
</table>

<h3>About Costco Wholesale</h3>
Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and enjoys over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 270 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.
Following our analysis of the options activities associated with Costco Wholesale, we pivot to a closer look at the company's own performance.
<h3>Costco Wholesale's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 656,907, the COST's price is down by -0.03%, now at $846.01. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>What The Experts Say On Costco Wholesale</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $931.4.
<ul>
<li>An analyst from B of A Securities persists with their Buy rating on Costco Wholesale, maintaining a target price of $962. </li>
<li>Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Costco Wholesale, targeting a price of $925. </li>
<li>Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Costco Wholesale, targeting a price of $950. </li>
<li>An analyst from Evercore ISI Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $920. </li>
<li>Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Costco Wholesale, targeting a price of $900. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Costco Wholesale options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

COST

Decoding Costco Wholesale's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bullish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 40 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 47% leaning bullish and 37% bearish. Among these notable options, 16 are puts, totaling $1,031,010, and 24 are calls, amounting to $1,098,039.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $490.0 to $820.0 for UnitedHealth Group over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of UnitedHealth Group stands at 1071.0, with a total volume reaching 7,195.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in UnitedHealth Group, situated within the strike price corridor from $490.0 to $820.0, throughout the last 30 days.
<h3>UnitedHealth Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721316723_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$9.0</td>
<td>$8.1</td>
<td>$9.0</td>
<td>$565.00</td>
<td>$222.2K</td>
<td>203</td>
<td style="text-align: right;">342</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$11.05</td>
<td>$12.25</td>
<td>$820.00</td>
<td>$161.7K</td>
<td>13.1K</td>
<td style="text-align: right;">36</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/23/24</td>
<td>$6.65</td>
<td>$5.8</td>
<td>$6.65</td>
<td>$605.00</td>
<td>$106.4K</td>
<td>10</td>
<td style="text-align: right;">4</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$6.7</td>
<td>$6.15</td>
<td>$6.45</td>
<td>$550.00</td>
<td>$98.6K</td>
<td>204</td>
<td style="text-align: right;">203</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$10.65</td>
<td>$10.15</td>
<td>$10.3</td>
<td>$590.00</td>
<td>$96.8K</td>
<td>1.1K</td>
<td style="text-align: right;">95</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the US as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Following our analysis of the options activities associated with UnitedHealth Group, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of UnitedHealth Group</h3>
<ul>
<li>With a trading volume of 2,511,383, the price of UNH is down by -1.2%, reaching $566.41.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 85 days from now.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $618.6.
<ul>
<li>An analyst from Jefferies has elevated its stance to Buy, setting a new price target at $647. </li>
<li>Maintaining their stance, an analyst from Argus Research continues to hold a Buy rating for UnitedHealth Group, targeting a price of $600. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $591. </li>
<li>Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for UnitedHealth Group, targeting a price of $615. </li>
<li>Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for UnitedHealth Group, targeting a price of $640. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on UNH Options

Whales with a lot of money to spend have taken a noticeably bearish stance on Visa.
Looking at options history for Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 60% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $61,164 and 8, calls, for a total amount of $723,595.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $280.0 for Visa over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Visa's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Visa's whale activity within a strike price range from $250.0 to $280.0 in the last 30 days. 
<h3>Visa Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721316718_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$13.1</td>
<td>$12.9</td>
<td>$13.0</td>
<td>$280.00</td>
<td>$182.0K</td>
<td>369</td>
<td>5</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$270.00</td>
<td>$143.4K</td>
<td>3.5K</td>
<td>445</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$9.0</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$270.00</td>
<td>$133.7K</td>
<td>3.5K</td>
<td>293</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$9.0</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$270.00</td>
<td>$88.8K</td>
<td>3.5K</td>
<td>138</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$8.75</td>
<td>$8.65</td>
<td>$8.65</td>
<td>$270.00</td>
<td>$52.7K</td>
<td>3.5K</td>
<td>1.4K</td>
</tr>
</tbody>
</table>

<h3>About Visa</h3>
Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
After a thorough review of the options trading surrounding Visa, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Visa Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,054,576, the price of V is down by -0.28%, reaching $271.95.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 5 days from now.</li>
</ul>
<h3>Expert Opinions on Visa</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $309.0.
<ul>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Visa with a target price of $330. </li>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Visa with a target price of $300. </li>
<li>In a cautious move, an analyst from B of A Securities downgraded its rating to Neutral, setting a price target of $297. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Visa, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Visa Options Trading: A Deep Dive into Market Sentiment

Virtu Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) shares are trading higher after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39834387/virtu-announces-second-quarter-2024-results" rel="noreferrer noopener">second-quarter financial results</a>.
The company registered adjusted earnings per share of 83 cents, beating <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the street view of 60 cents.</a>
Quarterly adjusted net trading income totaled $385.08 million, beating the analyst consensus of $331.57 million.
Virtu reported an adjusted EBITDA&nbsp;of $217.5 million, with an adjusted EBITDA margin&nbsp;of 56.5%.
Total revenues increased 36.7% to $693.0 million for this quarter, compared to $506.9 million for the same period in 2023.&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/asia/24/07/39832197/apple-nvidia-supplier-tsmc-reports-strong-q2-results-amid-booming-demand-for-ai-chips-guides-q3-abov" rel="noreferrer noopener">Apple, Nvidia Supplier TSMC Reports Strong Q2 Results Amid Booming Demand For AI Chips, Guides Q3 Above Consensus: 2024 To Be ‘Strong Growth Year,' Says CEO</a>
As of June 30, Virtu had $716.7 million in cash, cash equivalents and restricted cash, and total long-term debt outstanding in an aggregate principal amount of $1.766 billion.
Virtu&#8217;s board of directors declared a quarterly cash dividend of $0.24 per share. This dividend is payable on September&nbsp;15 to shareholders of <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">record as of September&nbsp;1.</a>
Including the additional $500 million authorization by its Board on April 24, the company has approximately $538.6 million remaining capacity for future purchases of shares of Class A Common Stock and Virtu Financial Units under the program.
Price Action: VIRT shares are trading higher by 18.6% to $27.89 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39823218/core-scientific-analyst-emphasizes-access-to-power-in-bitcoin-mining-assets-deal-wi" target="_blank" rel="noreferrer noopener">Core Scientific Analyst Emphasizes' Access To Power' In Bitcoin Mining Assets – Deal With CoreWeave Under Focus</a></li>
</ul>

Earnings

Equities

News

Dividends

Movers

General

VIRT

Why Is Virtu Financial Stock Jumping Today?

Barclays analyst Matt Miksic maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $430 to $490.

Price Target

Analyst Ratings

ISRG

Barclays Maintains Overweight on Intuitive Surgical, Raises Price Target to $490

Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) has outperformed the market over the past 10 years by 14.67% on an annualized basis producing an average annual return of 25.49%. Currently, Enphase Energy has a market capitalization of $14.95 billion. 
Buying $1000 In ENPH: If an investor had bought $1000 of ENPH stock 10 years ago, it would be worth $9,477.14 today based on a price of $109.84 for ENPH at the time of writing.
<h3>Enphase Energy's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721316622_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ENPH

Here's How Much $1000 Invested In Enphase Energy 10 Years Ago Would Be Worth Today

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) has outperformed the market over the past 10 years by 5.74% on an annualized basis producing an average annual return of 16.56%. Currently, Ross Stores has a market capitalization of $49.22 billion. 
Buying $100 In ROST: If an investor had bought $100 of ROST stock 10 years ago, it would be worth $465.81 today based on a price of $147.56 for ROST at the time of writing.
<h3>Ross Stores's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721316617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ROST

$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today

Stifel analyst W. Andrew Carter maintains Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) with a Hold and lowers the price target from $14.5 to $14.

HAYW

Stifel Maintains Hold on Hayward Holdings, Lowers Price Target to $14

As the public comment period for the Drug Enforcement Administration&#8217;s (DEA) <a href="https://www.benzinga.com/markets/cannabis/24/04/38531432/deas-move-to-reclassify-cannabis-seen-as-significant-but-fails-to-resolve-state-federal-conflict" target="_blank" rel="noreferrer noopener">proposal to reclassify marijuana as a Schedule III substance</a> under the Controlled Substances Act nears its July 22 deadline, the initiative has garnered significant public engagement. More than 33,000 comments have been submitted, reflecting a broad spectrum of opinions about cannabis policy in the U.S.
The proposal, initially published by the Department of Justice on May 21, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38905962/cannabis-rescheduling-when-will-it-happen-expert-lays-out-timeline-risks-and-wild-c" target="_blank" rel="noreferrer noopener">suggests moving cannabis from Schedule I</a>, which includes drugs deemed to have no medical use and a high potential for abuse, to Schedule III, which includes drugs with a lesser potential for abuse and accepted medical uses. This shift comes after the Department of Health and Human Services <a href="https://www.benzinga.com/markets/cannabis/23/08/34120876/health-officials-to-dea-ease-federal-restrictions-on-cannabis-will-this-set-stage-for-legalizati" target="_blank" rel="noreferrer noopener">recommended the reclassification</a>, acknowledging cannabis&#8217;s medical viability and lower abuse potential compared to substances like heroin and cocaine.
<h3 class="wp-block-heading">Broad Public Support For Rescheduling</h3>
Public sentiment, <a href="https://www.benzinga.com/markets/cannabis/24/05/39011156/exclusive-we-analyzed-4-000-dea-marijuana-rescheduling-comments-heres-what-americans-really-thin" target="_blank" rel="noreferrer noopener">as aggregated by Benzinga from over 4,000 comments</a>, shows wide support for rescheduling, with approximately 75.9% of feedback favoring the change. Many supporters emphasize the therapeutic benefits of cannabis and critique the outdated federal policies that do not align with current scientific understanding or state-level legalizations. However, a vocal minority insists on complete descheduling of cannabis, arguing that Schedule III status <a href="https://www.benzinga.com/markets/cannabis/24/06/39441930/why-descheduling-not-just-rescheduling-cannabis-could-swing-the-2024-election" target="_blank" rel="noreferrer noopener">still imposes unnecessary federal restrictions</a>.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38920897/infographic-deas-proposed-rules-for-marijuana-what-you-need-to-know" target="_blank" rel="noreferrer noopener">[Infographic] DEA&#8217;s Proposed Rules For Marijuana: What You Need To Know</a>
<h3 class="wp-block-heading">Clashing Views On DEA Rescheduling Proposal</h3>
Dr. Peter Grinspoon, a cannabis specialist at Harvard Medical School, emphasized in his public comment, &#8220;Cannabis should be descheduled not rescheduled&#8230;it is markedly less harmful than tobacco or alcohol&#8230;and has vast therapeutic use,&#8221; <a href="https://www.cannabisbusinesstimes.com/news/30000-plus-comments-submitted-dea-proposed-rescheduling-cannabis-rule/" target="_blank" rel="noreferrer noopener">noted</a> Cannabis Business Times. This sentiment is echoed by the U.S. Cannabis Council&#8217;s executive director Edward Conklin, who in his comments praised the DEA&#8217;s action as &#8220;historic,&#8221; potentially leading to broader public health benefits and more robust cannabis research.
On the other end, opposition voices, represented in a comment by Smart Approaches to Marijuana argues that rescheduling could boost the cannabis industry similarly to big tobacco, potentially increasing cannabis use and associated harms, especially among youth.
<h3 class="wp-block-heading">Students Urged To Comment On Rescheduling</h3>
Anna Meyer, a legislative intern for Drug Policy Alliance, highlighted in a recent Filter Mag <a href="https://filtermag.org/marijuana-federal-schedule-college-students/" target="_blank" rel="noreferrer noopener">article</a> that many college students, especially those from marginalized backgrounds, are unaware of the remaining opportunity to submit public comments on cannabis rescheduling. Meyer emphasized that federal prohibition continues to impose severe legal and educational consequences on students, such as loss of financial aid and future job prospects. Leveraging this comment period could push for descheduling, which she argues is necessary to fully eliminate these harms.
<h3 class="wp-block-heading">Deadline Nears For Public Comments Submission</h3>
As the deadline for public commentary approaches, the volume and content of responses underscore the importance Americans place on cannabis. For those interested in participating in this pivotal decision, comments can be submitted electronically through the Federal Register <a href="https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana" target="_blank" rel="noreferrer noopener">portal</a> or by mail to the DEA until the evening of July 22.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39828910/kentucky-gov-andy-beshear-to-dea-reschedule-cannabis-marijuana-products-will-reduce-suffering" target="_blank" rel="noreferrer noopener">Kentucky Gov Andy Beshear To DEA: Reschedule Cannabis &#8216;Marijuana Products Will Reduce Suffering&#8217;</a></li>
</ul>
Image generated with AI tools.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.

Cannabis

Government

Regulations

Over 33,000 Comments Flood DEA's Cannabis Rescheduling Proposal As July 22 Submission Deadline Looms

Stifel analyst Nathan Jones maintains Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) with a Buy and raises the price target from $55 to $58.

Stifel Maintains Buy on Flowserve, Raises Price Target to $58

TD Cowen analyst Jason Seidl maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Hold and lowers the price target from $161 to $160.

JBHT

TD Cowen Maintains Hold on JB Hunt Transport Servs, Lowers Price Target to $160

Vineyard Wind Says 'Significant Part' Of Remaining Blade Detached From Turbine Off Massachusetts Coast, More Debris Could Wash Ashore

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $621 to $611.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $611

Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) reported second-quarter FY24 revenue of $3.57 billion, missing the <a href="https://www.benzinga.com/pressreleases/24/07/b39825109/kinder-morgan-reports-second-quarter-2024-financial-results" target="_blank" rel="noreferrer noopener">consensus of $4.12 billion</a>.
Natural Gas Pipelines segment saw improved financial performance Y/Y, driven by higher contributions from the Texas Intrastate system and the STX Midstream acquisition.
Also, contributions from the Products Pipelines segment increased Y/Y, aided by higher rates on existing assets and contributions from new capital projects.
In the second quarter, earnings in the Terminals business segment exceeded Y/Y, led by new expansion projects coming online and increased rates and utilization at their New York Harbor hub facilities in liquids terminals.
CO2 business segment earnings, excluding the gain from a divestiture, were down due to lower crude volumes, CO2 sales, and NGL volumes, down 13%, 8%, and 17% respectively, on a net-to-KMI basis.
Adjusted EPS rose 4% Y/Y to&nbsp;$0.25, missing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;$0.26</a>.
The project backlog increased to $5.2 billion by the end of the second quarter of FY24 from $3.3 billion in the first quarter of FY24.
Kinder Morgan anticipates that the remaining $3.8 billion of projects in the backlog will generate an average Project EBITDA multiple of around 5.4 times.
The board of directors approved a cash dividend per share of $0.2875 for the second quarter, payable on August 15, 2024, to stockholders of record as of July 31, 2024.
The company generated cash flow from operations of $1.7 billion and $1.1 billion in free cash flow (FCF) after capital expenditures.
The company plans to allocate around 80% of its project backlog to investments in lower-carbon energy, such as conventional natural gas, renewable natural gas (RNG), renewable diesel (RD), RD feedstocks, sustainable aviation fuel (SAF), and carbon capture and sequestration initiatives.
Richard D. Kinder, Executive Chairman, said, &#8220;As I noted last quarter, we expect demand for natural gas to grow substantially between now and 2030, led by more than a doubling of demand for LNG exports and an almost 50% increase in natural gas exports to Mexico.&#8221;
The company expects to be roughly in-line with its budget for the full year (on budget or within 1-2% below).
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/05/38988778/kinder-morgan-acquires-west-texas-oilfield-to-leverage-carbon-capture-incentives-report" rel="noreferrer noopener">Kinder Morgan Acquires West Texas Oilfield To Leverage Carbon Capture Incentives: Report</a>
Price Action: KMI shares are up 3.19% at $21.19 at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Large Cap

Guidance

Kinder Morgan Q2: Earnings Miss, Higher Project Backlog & More

Stifel analyst Nathan Jones maintains ESAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESAB#NYSE">ESAB</a>) with a Buy and lowers the price target from $130 to $120.

ESAB

Stifel Maintains Buy on ESAB, Lowers Price Target to $120

United Airlines Exec Says Demand For Flights To China Is Down Dramatically Versus 2019

Stifel analyst Nathan Jones maintains Dnow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNOW#NYSE">DNOW</a>) with a Buy and raises the price target from $16 to $17.

DNOW

Stifel Maintains Buy on Dnow, Raises Price Target to $17

RDZN

Roadzen CEO And Chairman To Exchange $3.5M Of Short-Term Debt For Company Equity

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower amid recent weakness in tech stocks.

ZVSA

ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.59%

Mallinckrodt reports Q4 results

MCKPF

Small Cap

Press Releases

Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients